Table 2.
Events | Entire cohort | Ongoing ticagrelor | Stopped ticagrelor | P-value* |
---|---|---|---|---|
Composite endpoints | 20 (8.8) | 9 (5.0) | 11 (23.4) | <0.001 |
Myocardial infarction | 9 (4.0) | 6 (3.3) | 3 (6.4) | NS |
Death from vascular causes | 7 (3.1) | 2 (1.1) | 5 (10.6) | <0.005** |
Stroke | 4 (1.8) | 1 (0.6) | 3 (6.4) | <0.05** |
Notes:
Compared with ticagrelor ongoing therapy group.
Fisher’s exact test used to correct for small cell sizes. Composite endpoints include myocardial infarction, death from vascular cause, and/or stroke. Values are n (%).
Abbreviation: NS, not significant.